What kind of company is Aimovig?

Aimovig is a prescription medication developed and marketed by Amgen Inc. in collaboration with Novartis. It is indicated for the preventive treatment of migraines in adults. Aimovig is a calcitonin gene-related peptide (CGRP) receptor inhibitor , which means it helps to block the activity of CGRP, a chemical involved in migraines.

The development of Aimovig represents a significant advancement in the treatment of migraines, as it targets the underlying mechanisms of the condition rather than merely alleviating symptoms. By inhibiting the CGRP receptor, Aimovig aims to reduce the frequency and intensity of migraines in individuals who experience them.

It is worth noting that Aimovig is administered via subcutaneous injection and is intended for use by healthcare professionals in a clinical setting. The dosing and administration guidelines for Aimovig should be followed as prescribed by a healthcare provider.

Aimovig received approval from the U.S. Food and Drug Administration (FDA) in 2018 as the first CGRP inhibitor approved for the preventive treatment of migraines. Since then, it has become available to patients in the United States and has gained recognition as a promising treatment option for individuals who suffer from migraines.

Amgen and Novartis have collaborated in the marketing and distribution of Aimovig. This collaborative effort has allowed for the effective commercialization and widespread availability of the medication to reach patients in need.

As with any medication, Aimovig may have potential side effects or contraindications, and it is important for individuals interested in this treatment to consult with their healthcare providers to determine if it is appropriate for them.

Please note : The information provided here is based on the search results and general knowledge. For specific and up-to-date information about Aimovig, it is always recommended to consult official sources such as the product's website and healthcare professionals.